New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
March 3, 2025 - Celltrion announced the FDA approval of Osenvelt (denosumab-bmwo), biosimilar to Amgen’s Xgeva® (denosumab).
Download PDF
Return to publications
